Ads
related to: acute myeloid leukemia treatment- Trasfusion Independence
Discover A Potential Treatment
Option For Your Patients.
- Watch A Video On The MOA
Access Physician MOA Video
Materials On HCP Rx Site.
- Management Considerations
Learn About Disease-Related Factors
Like Molecular Abnormalities.
- Testing For Mutations
Find Mutation Testing Information
For Your Patients With R/R AML.
- View Safety Profile
View The Safety Profile For
A R/R AML Treatment Option.
- Physician Rx Resources
Find Clinical Resources, Videos,
And A HCP Testing Brochure.
- Trasfusion Independence
Search results
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology...
Digital Journal· 7 days agoTUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 7 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including...
FOX 23 News Albany· 3 days agoIn the results, olverembatinib showed excellent durable clinical benefits and favorable long-term tolerability in patients who had been treated with multiple TKIs (including those who were resistant ...
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Digital Journal· 4 days agoOperations Update LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments< ...
Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com
ETF DAILY NEWS· 1 day agoStockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report report published on Wednesday morning. The firm issued a sell rating on the ...
Incyte (NASDAQ:INCY) Earns Neutral Rating from Cantor Fitzgerald
ETF DAILY NEWS· 1 day agoIncyte (NASDAQ:INCY – Get Free Report)‘s stock had its “neutral” rating restated by research analysts at Cantor Fitzgerald in a research note issued on Tuesday, Benzinga reports. A number of ...
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Zacks· 7 days agoSL-172154 is an investigational agonist redirected checkpoint fusion protein, designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor ...
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
InvestorPlace· 4 days agoYou don’t want to overlook these three penny stocks filled to the brim with the potential to make...
Aptose Announces Results from Annual and Special Meeting of Shareholders
Digital Journal· 2 days agoFor more information, please visit www.aptose.com. Forward...
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's...
Benzinga· 3 days agoTakeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and ...
Ads
related to: acute myeloid leukemia treatment